Floatz logo

Pembrolizumab

Oral Cavity

VLP Therapeuticsmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Oral Cavity cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 3BB
CALCIUM PHOSPHATE
Impaqtt Foundation
Phase 3BB
Carboplatin
Radiation Therapy Oncology Group
Phase 3BB
Amifostine
Radiation Therapy Oncology Group
Phase 3B
Ifosfamide
Jonsson Comprehensive Cancer Center
Phase 2B

View all 12 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →